[The effect of the clinically usual cytostatic therapy on cell-mediated immune reactions in tumor patients].
D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery; D001984:Bronchial Neoplasms / Q000188:drug therapy; D002464:Cell Migration Inhibition; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005464:Fluorobenzenes / Q000276:immunology; D005472:Fluorouracil / Q000627:therapeutic use*; D007114:Immunization; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008264:Macrophages / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000276:immunology*; D009578:Nitrobenzenes / Q000276:immunology; D014374:Tuberculin Test
D005464:Fluorobenzenes; D009578:Nitrobenzenes; D003520:Cyclophosphamide; D005472:Fluorouracil
Die Auswirkung der klinisch üblichen Zytostatikatherapie auf zellvermittelte Immunreaktionen bei Tumorpatienten